Middle East Biomarker-Based Immunoassays Market (2025 - 2033)

Middle East Biomarker-Based Immunoassays Market Summary

The Middle East biomarker-based immunoassays market size was estimated at USD 114.23 million in 2024 and is projected to reach USD 159.25 million by 2033, growing at a CAGR of 3.61% from 2025 to 2033. The market growth is driven by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools. Increasing demand for personalized medicine has led clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring.

Countries such as Saudi Arabia, the UAE, and Kuwait are growing and investing heavily in diagnostic infrastructure and adopting international best practices. A growing trend in the market is the push for deeper partnerships between global diagnostic firms and local healthcare providers. A recent example came in January 2025, when Diatech Pharmacogenetics broadened its work with Merck to give colorectal cancer patients in the Middle East better access to RAS biomarker testing. Moves like this show how strongly the region is leaning toward personalized cancer care. These alliances do not just improve the reach of biomarker assays-they also bring new technologies into local systems and build expertise on the ground. For many international companies, the Middle East is starting to look like one of the most promising areas for growth in precision diagnostics.

The Middle East region offers untapped potential for biomarker-based immunoassays due to its expanding healthcare infrastructure and growing demand for precision medicine. Governments in countries like Saudi Arabia and the UAE have been putting serious money into diagnostic capacity so they do not have to rely as much on overseas labs. That shift is opening the door for local manufacturing and technology transfer. At the same time, lifestyle-driven diseases are becoming more common, which makes early detection and personalized treatment more important in areas such as oncology, cardiology, and neurology. With more attention now on value-based care, biomarker testing is seen as a practical way to lower costs while still improving patient outcomes.

Strategic collaborations are playing an important role in driving the Middle East biomarker ecosystem. In 2025, Diatech Pharmacogenetics expanded its partnership with Merck to improve colorectal cancer care in the region through RAS biomarker testing, highlighting the momentum in companion diagnostics. Similarly, partnerships between diagnostic technology providers like IBL International and Grifols are advancing biomarker panels that could see uptake in the Middle East’s expanding clinical research networks. In the meantime, regional organizations are demonstrating their dedication to becoming a center for precision diagnostics innovation by introducing cutting-edge biomarker testing programs that work with international standards, such as King Faisal Specialist Hospital in Saudi Arabia.

Market Concentration & Characteristics

The Middle East biomarker-based immunoassays industry reflects a medium degree of innovation, with global players introducing advanced blood and saliva-based assays while local firms focus on distribution and adaptation rather than in-house R&D. Most product innovation is import-led, with multinational IVD companies introducing updated reagents/kits and analyzers that fit existing CE-IVD/ISO frameworks. Local innovation concentrates on service delivery: decentralized sample collection, hub-and-spoke logistics, connectivity to LIS/HIS, and verification/validation of global assays for local populations.

The market has experienced a moderate level of merger and acquisition activity, with companies aiming to broaden their product portfolios and strengthen technological capabilities. Private hospital groups and insurance-backed providers in the GCC continue to integrate diagnostics to control turnaround time and cost, often via joint ventures or management agreements rather than outright acquisitions.

Many Middle East markets accept CE-IVD marking and ISO 13485 as baseline evidence, with additional local registration at national authorities (e.g., SFDA in Saudi Arabia, MOHAP/DOH in the UAE, and national drug/device authorities in Egypt, Morocco, Kenya). GCC unified procurement and Saudi’s NUPCO frameworks influence platform selection by tying reimbursement and supply to approved vendor lists and performance criteria.

Product expansion in the Middle East biomarker-based immunoassays industry has been largely import-driven, with multinational IVD companies introducing expanded reagent kits and analyzers tailored to oncology, infectious disease, and neurology. Cancer biomarker menus-particularly for breast, lung, and colorectal cancers-have gained traction in tertiary hospitals and specialized centers across Saudi Arabia, the UAE, Oman, and Qatar, where screening initiatives are expanding. Infectious disease remains a critical driver, with companies continuing to introduce immunoassay products for HIV, hepatitis, and tuberculosis, often supported by global health programs.

Regional expansion in the Middle East is driven by rising demand for accessible and timely diagnostics, especially as healthcare infrastructure develops outside capital cities. In the GCC, expansion strategies focus on integrating advanced immunoassay platforms into new hospital projects and diagnostic networks, particularly in Saudi Arabia’s Vision 2030 healthcare transformation and the UAE’s private hospital growth.

Sample Insights

The blood segment led the market in 2024 with a revenue share of 57.17%. Blood-based assays are commonly utilized for oncology, infectious diseases, and cardiovascular testing owing to their high precision, established clinical protocols, and seamless integration into hospital and reference laboratory environments. In the GCC, especially in Saudi Arabia and the UAE, the need for advanced blood-based biomarker tests is driven by government-led precision medicine programs and large-scale cancer screening programs. For example, Saudi Arabia's Ministry of Health has been working hard to expand national cancer screening campaigns as part of Vision 2030, which stresses early detection through advanced diagnostics.

The saliva segment is anticipated to grow at the fastest CAGR of 3.99% over the forecast period. Saliva-based tests are becoming more popular in wellness testing, diagnosing infectious diseases, and preventive healthcare programs, especially in urban areas of the GCC, where health monitoring by consumers is becoming more common. Countries like the UAE are early adopters of saliva-based biomarker platforms in corporate wellness programs and personalized health services. This shows that more people are becoming aware of preventive diagnostics. In Oman, saliva testing holds strong potential for infectious disease detection due to its ease of collection in low-resource and rural settings where blood sampling may not be feasible.

Product Insights

The reagents & kits segment led the market with the largest revenue share of 41.90% in 2024. Reagents and kits form the core of biomarker-based immunoassay activity across the Middle East, and they lead the market because they are the practical engine of clinical testing. Hospitals, public reference laboratories, and private diagnostic chains depend on validated, automation-ready kits that integrate smoothly with existing analyzers and quality systems. In GCC countries, ministries of health and large private providers prioritize platforms with stable reagent supply, traceable lot control, and strong vendor service levels. This favors standardized reagent menus for oncology (e.g., tumor markers), infectious disease (HIV, hepatitis, TB-related serology), cardiometabolic risk (troponin, BNP, HbA1c immunoassay formats), and women’s health.

The instruments/analyzers segment is anticipated to grow at the fastest CAGR of 4.2% over the forecast period. Instruments and analyzers are growing fastest as Middle East countries upgrade laboratory infrastructure. GCC hospitals are replacing legacy platforms with high-throughput analyzers offering better connectivity, automation, and uptime. Oman and regional hubs use standardized analyzers to support "hub-and-spoke" models, which make testing more centralized. As labs add cancer and neurological biomarkers to their menus, the need for overseas referrals goes down, which is also driving up the use of analyzers. Vendors are helping growth by offering training centers, financing options, and local service support. Overall, demand for modernized platforms that deliver speed, accuracy, and scalability is making analyzers the fastest-growing product segment in the Middle East.

Biomarker Insights

Based on biomarkers, the efficacy & pharmacodynamic biomarkers segment led the market with the largest revenue share of 34.67% in 2024. Hospitals and specialty centers in GCC states rely on these biomarkers to guide precision oncology and chronic disease management, while in the UAE, their use is growing through clinical trial collaborations and government-backed cancer programs. In Oman, private laboratories increasingly employ these biomarkers to support individualized therapies and improve patient outcomes.

The predictive & prognostic biomarkers segment is expected to grow at the fastest CAGR of 3.86% over the forecast period. A number of private labs are investing in prognostic testing to help with preventive healthcare and lower the cost of long-term care. Partnerships between global companies and regional research institutes are speeding up adoption even more, especially in the fields of neurology and oncology.

Diseases Insights

Based on diseases, the cancer segment led the market with the largest revenue share of 38.02% in 2024. Hospitals in the GCC make significant investments in biomarker testing for colorectal, lung, and breast cancers, and government funding for cancer programs is huge. The private sector in Oman has emerged as a major force, providing advanced biomarker panels to enable tailored therapies and focused treatments. With pharmaceutical companies conducting clinical trials in the areas that depend on cancer biomarker testing, international collaborations are also very important. Oncology remains the largest disease area for biomarker-based immunoassays in the Middle East due to the growing cancer burden and the government's dedication to early detection.

The neurological diseases segment is expected to grow at the fastest CAGR during the forecast period. Neurological disorders represent the fastest-growing segment as Middle East countries face rising cases of Alzheimer’s, Parkinson’s, and other cognitive conditions linked to aging populations and lifestyle factors. In the GCC, hospitals are adopting blood-based and CSF biomarker tests for early Alzheimer’s diagnosis, with the help of international partnerships. Oman research institutions are increasingly participating in neurology-related clinical trials, expanding access to biomarker technologies. Oman is seeing growing demand from private healthcare providers offering advanced diagnostics for neurodegenerative diseases, often in collaboration with multinational diagnostic firms.

End Use Insights

Based on end use, the hospitals & clinics segment led the market with the largest revenue share of 45.83% in 2024. Hospitals and clinics act as the first point of care for patients, making them an important hub for the adoption of biomarker-based immunoassays across disease areas such as oncology, cardiology, and neurology. Furthermore, the rising integration of immunoassay platforms within hospital diagnostic workflows enables physicians to implement more personalized treatment strategies, particularly as biomarker-driven therapies are gaining more acknowledge.

The diagnostic laboratories segment is expected to grow at a considerable CAGR of 3.50% over the forecast period. Hospitals, which primarily use immunoassays for immediate clinical needs, and laboratories cater to large volumes of testing for clinical trials, public health programs, and specialized diagnostics, giving them a unique position in the ecosystem. The rising demand for outsourcing complex biomarker testing by pharmaceutical companies and smaller hospitals is further fueling growth in this segment.

Country Insights

The biomarker-based immunoassays market in the Middle East is expanding. Countries such as the UAE, Saudi Arabia, Qatar, and Oman are investing in advanced diagnostic capabilities, with oncology and infectious diseases being primary areas of focus. In 2024, Siemens Healthineers partnered with healthcare providers in the UAE to deploy new immunoassay analyzers for cancer biomarker testing, reflecting growing regional demand. While adoption levels remain lower compared to developed markets, increasing collaborations with global diagnostic leaders are driving accessibility.

The Saudi Arabia biomarker-based immunoassays industry is grow in. Saudi hospitals and research institutions are adopting biomarker-based immunoassays to mitigate growing cancer and cardiovascular disease prevalence. In 2024, King Faisal Specialist Hospital and Research Centre launched a new biomarker testing program for oncology patients, highlighting the country’s commitment to advanced diagnostics. Partnerships with international diagnostic players are also expanding biomarker assay availability, making Saudi Arabia an important growth node in the region. The increasing prevalence of Cardiovascular Diseases (CVDs) and rising awareness about them is expected to drive the market growth. According to ScienceDirect, by 2035, the prevalence of CVDs is estimated to reach 479,500. Similarly, according to the International Diabetes Atlas, in 2021, over 4.27 million people in the country had diabetes. In 2023, the nation is anticipated to witness a diagnosis of over 31,000 new cancer cases. Chronic diseases need constant support from diagnostics and immunoassays to make treatment possible, and thus, their growing prevalence is creating growth opportunities.

The UAE biomarker-based immunoassays industry is anticipated to grow at a healthy CAGR over the forecast period. As UAE is a high-income country, the UAE government aims to provide universal access to updated and advanced healthcare services. Due to its vast financial resources and adequate government funding, the UAE immunoassay market is growing at a steady pace. In addition, ongoing public-private initiatives to facilitate diagnosis of chronic diseases in the country are expected to create a conducive environment for growth.

The biomarker based immunoassays market in Kuwait is expected to promote the demand for diagnostic testing and support due to high burden of these diseases in the country. Due to the pandemic, the diagnostic device companies partnered with market players to improve testing in Kuwait. For instance, in March 2023, Mylab Discovery Solutions partnered with AstraGene, a diagnostic company, to develop automated molecular diagnostics for Kuwait. Adoption of such strategies and the high burden of COVID-19 in the country are expected to improve the availability of immunoassays in the region. Kuwait has shown an increased emphasis on early diagnosis and screening for improving patient outlook. Screening solutions have witnessed certain novel advancements, such as the adoption of immunoassays and precision diagnosis with biomarkers.

The market for biomarker-based immunoassays in Oman is emerging, supported by growing awareness of non-communicable diseases (NCDs) such as cancer, cardiovascular disease, and diabetes. Health system investments under Oman Vision 2040 are boosting diagnostic capacity. For example, demand for point-of-care immunoassay analyzers and blood gas analyzers has increased, as public and private sector hospitals upgrade their laboratories and decentralize testing.

Technological adoption trends are also significant: there is a rising use of microfluidics, mobile health (mHealth), telemedicine, and digital diagnostics, which can support immunoassay workflows. Oman is seeing greater interest in non-invasive sample types (e.g., saliva) and rapid diagnostic consumables as testing outside large hospitals becomes more common.

However, there remain challenges: many immunoassay tests are still imported, raising cost and supply chain risks; rural and remote areas have lower access; and regulatory or reimbursement frameworks are less mature compared to GCC peers. Oman’s market growth will depend largely on continued investment in infrastructure, improved regulatory clarity, and greater local or regional partnerships for assay validation and supply.

Qatar biomarker-based immunoassays industry is pushing forward on precision diagnostics and biomarker innovations, using strong institutional capacity and funding to lead regional adoption. A good example is from March 2025, when Sidra Medicine published a study showing distinct blood and salivary proteomics signatures for individuals at high risk of cardiovascular disease, pointing toward non-invasive assays as practical tools for early detection and screening. Also, in September 2025, Hamad Medical Corporation (HMC), via its Department of Laboratory Medicine and Pathology, launched Whole Exome Sequencing (WES) testing in-house. Previously, such tests had to be sent abroad. This strengthens local infrastructure, reduces turnaround time, and enhances deployment of biomarker assays.

Key Middle East Biomarker-Based Immunoassays Company Insights

Key participants in the biomarker-based immunoassays market in the Middle East are focusing on developing innovative testing solutions and securing necessary certifications to broaden their offerings. In addition, companies are entering into partnerships, collaborations, mergers, and acquisitions to strengthen their presence in the sector. These players are heavily investing in advanced technology and infrastructure, allowing them to efficiently process and analyze a large volume of samples. Moreover, companies undertake various strategic initiatives with other companies and distributors to strengthen their market presence.

Recent Developments

• In January 2025, Diatech Pharmacogenetics announced an expanded partnership with Merck to improve access to RAS (KRAS and NRAS) biomarker testing for colorectal cancer across the Middle East and Africa, underlining Saudi’s role as a regional hub for personalized diagnostics.

• In January 2025, Abu Dhabi inaugurated a new Alzheimer’s Detection Centre, introducing an advanced blood test for early diagnosis of the disease. The initiative was developed through a collaboration between the National Reference Laboratory (NRL) and Neurocode International, with global experts Prof. Henrik Zetterberg and Prof. Kaj Blennow contributing as scientific consultants. The centre aims to provide more accessible and less invasive diagnostic solutions by using biomarker-based blood assays to detect amyloid pathology at earlier stages.

Middle East Biomarker-Based Immunoassays Market